iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin's Lymphoma.
children
isobaric tags for relative and absolute quantification (iTRAQ)
non-Hodgkin’s lymphoma
proteomics
serum
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
01
2022
accepted:
21
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Non-Hodgkin's lymphoma (NHL) is the third most common malignant tumor among children. However, at initial NHL diagnosis, most cases are at an advanced stage because of nonspecific clinical manifestations and currently limited diagnostic methods. This study aimed to screen and verify potential serum biomarkers of pediatric NHL using isobaric tags for relative and absolute quantification (iTRAQ)-based proteomic analysis. Serum protein expression profiles from children with B-NHL (n=20) and T-NHL (n=20) and healthy controls (n=20) were detected by utilizing iTRAQ in combination with two-dimensional liquid chromatography-tandem mass spectrometry (2D LC-MS/MS) and analyzed by applying Ingenuity Pathway Analysis (IPA). The candidate biomarkers S100A8 and LRG1 were further validated by using enzyme-linked immunosorbent assays (ELISAs). Receiver operating characteristic (ROC) analysis based on ELISA data was used to evaluate diagnostic efficacy. In total, 534 proteins were identified twice using iTRAQ combined with 2D LC-MS/MS. Further analysis identified 79 and 73 differentially expressed proteins in B-NHL and T-NHL serum, respectively, compared with control serum according to our defined criteria; 34 proteins were overexpressed and 45 proteins underexpressed in B-NHL, whereas 45 proteins were overexpressed and 28 proteins underexpressed in T-NHL (
Identifiants
pubmed: 35371990
doi: 10.3389/fonc.2022.848286
pmc: PMC8970600
doi:
Types de publication
Journal Article
Langues
eng
Pagination
848286Informations de copyright
Copyright © 2022 Yu, Cheng, Yang, Liu and Zhu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Semin Oncol. 1980 Sep;7(3):332-9
pubmed: 7414342
Clin Cancer Res. 2012 Oct 15;18(20):5617-27
pubmed: 22904106
Nature. 2013 Jul 18;499(7458):306-11
pubmed: 23868260
EBioMedicine. 2019 Dec;50:211-223
pubmed: 31753726
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Oncogene. 2016 Nov 3;35(44):5735-5745
pubmed: 27086923
Mol Ther Nucleic Acids. 2018 Jun 1;11:538-553
pubmed: 29858089
Mol Oncol. 2016 Oct;10(8):1363-73
pubmed: 27491861
J Clin Oncol. 2015 Sep 20;33(27):2963-74
pubmed: 26304908
Am J Transl Res. 2015 Dec 15;7(12):2775-85
pubmed: 26885274
Cell Death Dis. 2017 Oct 5;8(10):e3071
pubmed: 28981108
Stem Cells. 2020 Jan;38(1):6-14
pubmed: 31648395
N Engl J Med. 1996 May 9;334(19):1238-48
pubmed: 8606720
Biomark Res. 2016 Jan 27;4:1
pubmed: 26823978
EMBO Mol Med. 2015 Aug 07;7(9):1153-65
pubmed: 26253080
N Engl J Med. 2007 Nov 22;357(21):2195-7
pubmed: 18032771
Cancers (Basel). 2020 Jul 19;12(7):
pubmed: 32707720
J Natl Cancer Inst. 2019 Apr 1;111(4):372-379
pubmed: 30137376
Blood. 2017 Apr 6;129(14):1980-1990
pubmed: 28137827
FEBS J. 2018 Feb;285(3):432-443
pubmed: 28971574
J Cancer Prev. 2016 Sep;21(3):187-193
pubmed: 27722145
Mol Ther Oncolytics. 2019 Aug 07;14:313-322
pubmed: 31528707
Mol Cancer Res. 2012 Oct;10(10):1319-31
pubmed: 22912335
Int J Lab Hematol. 2021 Aug;43(4):638-644
pubmed: 33904653
J Proteome Res. 2006 Mar;5(3):651-8
pubmed: 16512681
Semin Cancer Biol. 2012 Jun;22(3):216-25
pubmed: 22381352
Br J Haematol. 2019 Jun;185(6):1158-1170
pubmed: 30809797
Nat Rev Drug Discov. 2014 Jun;13(6):433-44
pubmed: 24833295
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
N Engl J Med. 1999 Feb 11;340(6):448-54
pubmed: 9971870
Br J Pharmacol. 2021 Aug;178(16):3261-3276
pubmed: 32673401
J Proteomics. 2016 Feb 5;133:93-99
pubmed: 26710722
EMBO Mol Med. 2015 Aug 07;7(9):1166-78
pubmed: 26253081
Blood. 2020 Apr 2;135(14):1124-1132
pubmed: 31961927
Cancers (Basel). 2021 Jun 30;13(13):
pubmed: 34208965
Ann Oncol. 2010 Jul;21(7):1472-1481
pubmed: 20022911
J Clin Invest. 2006 Mar;116(3):607-14
pubmed: 16511593
Med Sci Monit. 2018 Nov 20;24:8348-8356
pubmed: 30455412
Oncol Lett. 2017 Dec;14(6):7676-7680
pubmed: 29250170
Br J Haematol. 2019 Jun;185(6):1021-1042
pubmed: 30729513
Front Oncol. 2021 Jan 29;10:566804
pubmed: 33585190
Nat Rev Cancer. 2015 Apr;15(4):216-24
pubmed: 25786697
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8471-8480
pubmed: 30971492
J Cancer. 2020 Feb 3;11(8):2252-2264
pubmed: 32127952
J Cancer. 2021 Jan 15;12(6):1651-1659
pubmed: 33613752
Cancer Res Treat. 2020 Apr;52(2):359-368
pubmed: 31352772
Leukemia. 2011 Jan;25(1):57-65
pubmed: 21072048
Cancers (Basel). 2020 Jul 24;12(8):
pubmed: 32722137
Nature. 2007 Dec 13;450(7172):991-1000
pubmed: 18075578
Oncol Rep. 2021 Jan;45(1):151-158
pubmed: 33169801
Life Sci. 2021 May 15;273:119287
pubmed: 33667512
Immunol Cell Biol. 2017 Apr;95(4):325-332
pubmed: 27999432
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Cancer Manag Res. 2019 Jul 25;11:7047-7063
pubmed: 31440093
J Oral Pathol Med. 2018 Oct;47(9):900-906
pubmed: 29998578
Nat Protoc. 2017 Aug;12(8):1683-1701
pubmed: 28749931